Anastrozole, an aromatase inhibitor, reduces estrogen receptor (ER)-positive breast cancer growth by suppressing estrogen synthesis, thereby limiting tumor proliferation (Milani et al., 2009). Here, CYP19A1 is linked to breast carcinoma.